glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 Agonists: Revolutionizing the Treatment

Back Carlsson, LMS, Carlsson, B, Jacobson, P, et al (12 July 2023) 'Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish obese subjects', International Journal of Obesity (London) , 47/10

The release of proglucagon causes the liver to make glucose (gluconeogenesis converting protein to glucose) as well as to convert fatty acids into ketone bodies

Am Fam Physician

In just 30 to 40 seconds, this noninvasive scan captures a detailed 3D map of your body, assessing your unique shape and composition

a high-quality EG3G extract can enhance your bodys natural digestive function to make it more efficient at breaking down food, transferring nutrients, and eliminating toxins